{
    "1X8.F": {
        "short_name": "CRESO PHARMA LTD",
        "long_name": "Creso Pharma Limited",
        "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX\u00c2\u00aenite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "41C.SG": {
        "short_name": "CannPal Animal Therapeut. Ltd.R",
        "long_name": "CannPal Animal Therapeutics Limited",
        "summary": "CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Australia",
        "city": "Double Bay"
    },
    "AC8.AX": {
        "short_name": "AUSCANN FPO",
        "long_name": "AusCann Group Holdings Ltd",
        "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "West Perth"
    },
    "ACNNF": {
        "short_name": "AUSCANN GROUP HOLDINGS LTD",
        "long_name": "AusCann Group Holdings Ltd",
        "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "West Perth"
    },
    "AGH.AX": {
        "short_name": "ALTHEA FPO",
        "long_name": "Althea Group Holdings Limited",
        "summary": "Althea Group Holdings Limited cultivates, produces, supplies, imports, and exports pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, and Canada. It also offers a range of education, access, and management services to support eligible patients, healthcare professionals, and pharmacies in navigating medicinal cannabis treatment pathways through Concierge, an online service, as well as Medic, an online education. Althea Group Holdings Limited was founded in 2017 and is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "ANP.AX": {
        "short_name": "ANTISENSE FPO",
        "long_name": "Antisense Therapeutics Limited",
        "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Toorak"
    },
    "ATHJF": {
        "short_name": "ANTISENSE THERAPEUTICS",
        "long_name": "Antisense Therapeutics Limited",
        "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Toorak"
    },
    "CAU.AX": {
        "short_name": "CRONOS FPO",
        "long_name": "Cronos Australia Limited",
        "summary": "Cronos Australia Limited operates as a medicinal cannabis company in Australia and Asia. The company operates through Medicinal Cannabis and Clinics segments. It distributes  PEACE NATURALS brand medicinal cannabis products; develops and sells medicinal cannabis products; and operates medicinal cannabis clinics. The company was incorporated in 2018 and is headquartered in South Yarra, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "South Yarra"
    },
    "CNGGF": {
        "short_name": "CANN GROUP LTD",
        "long_name": "Cann Group Limited",
        "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Bundoora"
    },
    "COPHF": {
        "short_name": "CRESO PHARMA LTD",
        "long_name": "Creso Pharma Limited",
        "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX\u00c2\u00aenite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "CP1.AX": {
        "short_name": "CANNPAL FPO",
        "long_name": "CannPal Animal Therapeutics Limited",
        "summary": "CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Double Bay"
    },
    "CPH.AX": {
        "short_name": "CRESO FPO",
        "long_name": "Creso Pharma Limited",
        "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX\u00c2\u00aenite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "CVJ.F": {
        "short_name": "CANN GROUP LTD",
        "long_name": "Cann Group Limited",
        "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Bundoora"
    },
    "E8M.F": {
        "short_name": "ELIXINOL GLOBAL",
        "long_name": "Elixinol Global Limited",
        "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based dietary supplements and skincare products in the Americas, Europe, the United Kingdom, and Australia. The company distributes hemp-derived cannabidiol products under the Elixinol brand. It also acts as a wholesaler, retailer, manufacturer, and exporter of hemp food; offers hemp seeds, hemp protein, hemp oil, and hemp flour; and hemp-based Sativa skincare range, as well as grounded plant based burger range. The company was incorporated in 2017 and is based in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "ELLXF": {
        "short_name": "ELIXINOL GLOBAL LTD",
        "long_name": "Elixinol Global Limited",
        "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based dietary supplements and skincare products in the Americas, Europe, the United Kingdom, and Australia. The company distributes hemp-derived cannabidiol products under the Elixinol brand. It also acts as a wholesaler, retailer, manufacturer, and exporter of hemp food; offers hemp seeds, hemp protein, hemp oil, and hemp flour; and hemp-based Sativa skincare range, as well as grounded plant based burger range. The company was incorporated in 2017 and is based in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "EOF.AX": {
        "short_name": "ECOFIBRE FPO",
        "long_name": "Ecofibre Limited",
        "summary": "Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia. It offers protein powders, dehulled hemp seeds, and hemp seed oil products. The company also produces hemp nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. It sells its products through wholesalers and distributors, as well as pharmacy stores under the Ananda Food and Woolworths Macro brand names. The company was founded in 2009 and is based in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "EOFBF": {
        "short_name": "ECOFIBRE LTD",
        "long_name": "Ecofibre Limited",
        "summary": "Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia. It offers protein powders, dehulled hemp seeds, and hemp seed oil products. The company also produces hemp nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. It sells its products through wholesalers and distributors, as well as pharmacy stores under the Ananda Food and Woolworths Macro brand names. The company was founded in 2009 and is based in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "EXL.AX": {
        "short_name": "ELIXINOL FPO",
        "long_name": "Elixinol Global Limited",
        "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based dietary supplements and skincare products in the Americas, Europe, the United Kingdom, and Australia. The company distributes hemp-derived cannabidiol products under the Elixinol brand. It also acts as a wholesaler, retailer, manufacturer, and exporter of hemp food; offers hemp seeds, hemp protein, hemp oil, and hemp flour; and hemp-based Sativa skincare range, as well as grounded plant based burger range. The company was incorporated in 2017 and is based in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "IDT.AX": {
        "short_name": "IDT AUST FPO",
        "long_name": "IDT Australia Limited",
        "summary": "IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. The company offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services, as well as pharmaceutical development services in all dosage forms. Its services also include project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs. In addition, the company offers medical cannabis products; and various contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Boronia"
    },
    "IHL.AX": {
        "short_name": "INHEALTH FPO",
        "long_name": "Incannex Healthcare Limited",
        "summary": "Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has partnership with Monash University to conduct clinical trial. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "IQI.F": {
        "short_name": "INCANNEX HEALTHCARE LTD.",
        "long_name": "Incannex Healthcare Limited",
        "summary": "Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has partnership with Monash University to conduct clinical trial. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "IVIXF": {
        "short_name": "INVION LTD",
        "long_name": "Invion Limited",
        "summary": "Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "IVX.AX": {
        "short_name": "INVION FPO",
        "long_name": "Invion Limited",
        "summary": "Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LGP.AX": {
        "short_name": "LITTLEGRN FPO",
        "long_name": "Little Green Pharma Ltd",
        "summary": "Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. It offers a range of medical cannabis preparations in oil formulation under the LGP Natural and LGP Advanced names. The company was founded in 2016 and is headquartered in West Perth, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "West Perth"
    },
    "LV1.AX": {
        "short_name": "LIVEVLIM FPO",
        "long_name": "Live Verdure Ltd",
        "summary": "Live Verdure Ltd develops hemp plant-based solutions in Australia. The company offers hemp seed oil, seed oil capsules, infused manuka honey, honey, drinking chocolate, seed, greens, chai powder, porridge with dried fruit, falafel, health booster, falafel spicy, porridge, flour, food, muesli, protein powder, and falafel lemon and pepper. It distributes its products under the 13 Seeds brand name. The company was formerly known as 13 Seeds Pty Ltd and changed its name to Live Verdure Ltd in October 2020. Live Verdure Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "MGCLF": {
        "short_name": "MGC PHARMACEUTICALS LTD",
        "long_name": "MGC Pharmaceuticals Limited",
        "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "West Perth"
    },
    "MMJJF": {
        "short_name": "MMJ GROUP HOLDINGS LTD",
        "long_name": "MMJ Group Holdings Limited",
        "summary": "MMJ Group Holdings Limited operates as a cannabis investment company worldwide. It owns a portfolio of cannabis sector investments. The company was formerly known as MMJ PhytoTech Limited. MMJ Group Holdings Limited was incorporated in 2014 and is based in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "MVP.AX": {
        "short_name": "MEDICALDEV FPO",
        "long_name": "Medical Developments International Limited",
        "summary": "Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain relief; medical devices; and various veterinary anesthetic machines to veterinarians. The company operates in Australia, New Zealand, the United Kingdom, rest of Europe, Canada, the Middle East, Asia, South Africa, North America, and internationally. Medical Developments International Limited was incorporated in 2003 and is headquartered in Scoresby, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Scoresby"
    },
    "MXC.AX": {
        "short_name": "MGC PHARMA FPO",
        "long_name": "MGC Pharmaceuticals Limited",
        "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "West Perth"
    },
    "NXS.AX": {
        "short_name": "NEXTSCIENC FPO",
        "long_name": "Next Science Limited",
        "summary": "Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the United States and Australia. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne cream and cleanser. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "NXSCF": {
        "short_name": "NEXT SCIENCE LTD",
        "long_name": "Next Science Limited",
        "summary": "Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the United States and Australia. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne cream and cleanser. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "PARNF": {
        "short_name": "PARNELL PHARMACEUTICALS HLDGS L",
        "long_name": "Parnell Pharmaceuticals Holdings Ltd",
        "summary": "Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also operates mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Alexandria"
    },
    "PBP.AX": {
        "short_name": "PROBIOTEC FPO",
        "long_name": "Probiotec Limited",
        "summary": "Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, and ointments and suspensions; powders and powder blending; and sprays, as well as manufacturing and packaging of finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. In addition, the company provides packing services and formats, including foil, carded and clamshell blister packing, bottle filling, labelling, secondary packaging, and other services for the pharmaceutical, cosmetic, and food industries. Probiotec Limited was incorporated in 1996 and is headquartered in Laverton North, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Laverton North"
    },
    "RAP.SW": {
        "short_name": "Rapid Nutrition N",
        "long_name": "Rapid Nutrition PLC",
        "summary": "Rapid Nutrition PLC, a natural healthcare company, researches, develops, and produces a range of life science products. The company offers meal replacement shakes, energy boosting tablets, weight loss tablets, and appetite suppressant powders under the Leisa's Secret brand; and high protein shakes, high fiber bars, organic multivitamins, fat burning shots, and grain granola cereals under the SystemLS brand. It primarily exports its products in Asia, Europe, Africa, the Middle East, North America, and Australia. The company was incorporated in 2001 and is based in Meadowbrook, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Australia",
        "city": "Meadowbrook"
    },
    "RPNRF": {
        "short_name": "RAPID NUTRITION PLC",
        "long_name": "Rapid Nutrition PLC",
        "summary": "Rapid Nutrition PLC, a natural healthcare company, researches, develops, and produces a range of life science products. The company offers meal replacement shakes, energy boosting tablets, weight loss tablets, and appetite suppressant powders under the Leisa's Secret brand; and high protein shakes, high fiber bars, organic multivitamins, fat burning shots, and grain granola cereals under the SystemLS brand. It primarily exports its products in Asia, Europe, Africa, the Middle East, North America, and Australia. The company was incorporated in 2001 and is based in Meadowbrook, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Meadowbrook"
    },
    "SCU.AX": {
        "short_name": "STEMCELL FPO",
        "long_name": "Stemcell United Limited",
        "summary": "Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicine in Australia, Singapore, Greater China, and Malaysia. The company's products include Cannabis Sativa, an industrial hemp; Dendrobium Officinale Kimura et Migo, an orchid extract; Resina, a Daemonorops Draco Blume extract; and Caulerpa Lentillifera, a sea grape extract. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "USZ.F": {
        "short_name": "STEMCELL UNITED LTD",
        "long_name": "Stemcell United Limited",
        "summary": "Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicine in Australia, Singapore, Greater China, and Malaysia. The company's products include Cannabis Sativa, an industrial hemp; Dendrobium Officinale Kimura et Migo, an orchid extract; Resina, a Daemonorops Draco Blume extract; and Caulerpa Lentillifera, a sea grape extract. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "UVP.F": {
        "short_name": "AUSCANN GROUP HLDGS O.N.",
        "long_name": "AusCann Group Holdings Ltd",
        "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "West Perth"
    },
    "VLS.AX": {
        "short_name": "VLSCIENCE FPO",
        "long_name": "Vita Life Sciences Limited",
        "summary": "Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, sale, and distribution of vitamins and supplements. It offers a range of supplements, vitamins, minerals, herbs, and superfoods. The company markets its products through pharmacies and health food stores under the VitaHealth, Herbs of Gold, VitaScience, and VitaLife brand names. It operates in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, Hong Kong, and China. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Kirrawee"
    }
}